心房颤动负荷:新的结局预测指标与治疗目标
本文综述了心房颤动(AF)负荷与结局的关系及降低AF负荷的潜在效果。设备检测的低负荷AF患者不抗凝时卒中率约1%/年,低于持续/永久性AF的3%/年,阵发性AF居中为2%/年;早期节律控制与AF消融等降低负荷的干预可减少心血管事件、死亡和心衰事件。AF负荷减少正成为抗凝和心血管病治疗之外的治疗目标,但证据仍有限,需进一步验证量化技术。
要点
- AF负荷越低,卒中与心衰风险越低,设备检测低负荷AF不抗凝卒中率约1%/年。
- 早期节律控制和AF消融等降低AF负荷的干预可减少心血管事件、死亡和心衰事件。
- AF负荷减少可作为抗凝和心血管病治疗之外的治疗目标,但证据有限需验证。
核心结论
- 现有数据提示降低AF负荷可作为治疗目标,与抗凝和心血管病治疗并列。
研究设计与样本
- 综述,描述AF负荷与结局的关系及降低AF负荷的潜在效果。
主要发现
- 不抗凝时,设备检测低负荷AF卒中率1%/年,持续和永久性AF为3%/年,阵发性AF为2%/年。
- 早期节律控制可减少近期诊断AF且合并心血管疾病患者的心血管事件,包括卒中和心衰。
- 心衰合并AF患者中,早期节律控制和AF消融可降低死亡和心衰事件。
关键数值与推荐
- 设备检测低负荷AF不抗凝卒中率1%/年,持续和永久性AF为3%/年,阵发性AF为2%/年。
临床怎么用
- 在抗凝和心血管病治疗基础上,可考虑将降低AF负荷作为治疗目标。
- 利用技术量化AF负荷需仔细验证以推进该领域。
局限性
- 证据仍然有限。
- 未来研究需定义构成相关卒中和心衰风险的AF负荷。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Atrial fibrillation (AF), the most common sustained cardiac arrhythmia, is not a dichotomous disease trait. Technological innovations enable long-term rhythm monitoring in many patients and can estimate AF burden. These technologies are already used to detect and monitor AF. This review describes the relation between AF burden and outcomes and potential effects of AF burden reduction. A lower AF burden is associated with a lower risk of stroke and heart failure in patients with AF: stroke risk without anticoagulation is lower in patients with device-detected AF and a low AF burden (stroke rate 1%/year) than in patients with persistent and permanent AF (stroke rate 3%/year). Paroxysmal AF shows intermediate stroke rates (2%/year). Atrial fibrillation burden-reducing interventions can reduce cardiovascular outcomes in patients with AF: early rhythm control reduces cardiovascular events including stroke and heart failure in patients with recently diagnosed AF and cardiovascular conditions. In patients with heart failure and AF, early rhythm control and AF ablation, interventions that reduce AF burden, reduce mortality and heart failure events. Recent technological innovations allow to estimate AF burden in clinical care, creating opportunities and challenges. While evidence remains limited, the existing data already suggest that AF burden reduction could be a therapeutic goal. In addition to anticoagulation and treatment of cardiovascular conditions, AF burden reduction emerges as a therapeutic goal. Future research will define the AF burden that constitutes a relevant risk of stroke and heart failure. Technologies quantifying AF burden need careful validation to advance the field.
引用
- Becher, Metzner, Toennis, et al. Atrial fibrillation burden: a new outcome predictor and therapeutic target. Eur Heart J. 2024. PMID: 38953776. doi:10.1093/eurheartj/ehae373
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。